- Home
- TYRA vs PSNYW Comparison
TYRA vs PSNYW Comparison
Compare TYRA & PSNYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- PSNYW
- Stock Information
- Founded
- TYRA 2018
- PSNYW 2017
- Country
- TYRA United States
- PSNYW Sweden
- Employees
- TYRA N/A
- PSNYW 2547
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- PSNYW Auto Manufacturing
- Sector
- TYRA Health Care
- PSNYW Consumer Discretionary
- Exchange
- TYRA Nasdaq
- PSNYW Nasdaq
- Market Cap
- TYRA 571.9M
- PSNYW 625.2M
- IPO Year
- TYRA 2021
- PSNYW N/A
- Fundamental
- Price
- TYRA $12.45
- PSNYW $0.32
- Analyst Decision
- TYRA Strong Buy
- PSNYW
- Analyst Count
- TYRA 8
- PSNYW 0
- Target Price
- TYRA $31.00
- PSNYW N/A
- AVG Volume (30 Days)
- TYRA 235.9K
- PSNYW 43.4K
- Earning Date
- TYRA 11-06-2025
- PSNYW 03-06-2025
- Dividend Yield
- TYRA N/A
- PSNYW N/A
- EPS Growth
- TYRA N/A
- PSNYW N/A
- EPS
- TYRA N/A
- PSNYW N/A
- Revenue
- TYRA N/A
- PSNYW $2,034,261,000.00
- Revenue This Year
- TYRA N/A
- PSNYW N/A
- Revenue Next Year
- TYRA N/A
- PSNYW $79.49
- P/E Ratio
- TYRA N/A
- PSNYW N/A
- Revenue Growth
- TYRA N/A
- PSNYW N/A
- 52 Week Low
- TYRA $6.42
- PSNYW $0.09
- 52 Week High
- TYRA $29.60
- PSNYW $0.61
- Technical
- Relative Strength Index (RSI)
- TYRA 58.97
- PSNYW 58.48
- Support Level
- TYRA $11.70
- PSNYW $0.28
- Resistance Level
- TYRA $12.55
- PSNYW $0.35
- Average True Range (ATR)
- TYRA 0.68
- PSNYW 0.09
- MACD
- TYRA -0.03
- PSNYW 0.00
- Stochastic Oscillator
- TYRA 52.50
- PSNYW 26.33
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.